Clinical trialPhase 1Terminated
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.
- Outcome
- Stopped earlyAfter review of data which showed low likelihood of efficacy in these patients Novartis decided to terminate the trial early. Termination was not safety related (Efficacy or futility)
- Phase
- Phase 1
- Status
- Terminated
- Study type
- Interventional
- Start
- 18 July 2018
- Expected end
- 17 October 2022
- Enrollment
- 127 participants
- Sites
- 10
- Primary outcomes
- Number of participants with adverse events as a measure of safety and tolerability of the NZV930 in combination with PDR001 and/or NIR178
- Sponsor
- Industry
- Results posted
- No
- Last update
- 13 December 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers